TORONTO, Oct. 20, 2020 /CNW/ - NeuPath Health Inc. (TSX-V:NPTH) ("NeuPath" or the "Company"), Canada's largest provider of chronic pain management services, is pleased to announce that it has agreed with Stifel GMP as co-lead underwriter and sole bookrunner and INFOR Financial Inc. as co-lead underwriter, together with Haywood Securities Inc. (collectively, the "Underwriters"), to increase the size of its previously announced $8,001,000 bought deal offering. Pursuant to the upsized deal terms, the Underwriters have agreed to purchase, on a "bought deal" basis, 11,600,000 units of the Company (the "Units") at a price of $0.90 per Unit, for aggregate gross proceeds of $10,440,000. The Underwriters will also have the option, exercisable in whole or in part at any time on or up to 30 days after the Closing Date (as defined herein), to purchase up to an additional 1,740,000 Units. In the event that the option is exercised in full, the aggregate gross proceeds of the offering will be $12,006,000.

Click here to see the full PDF Press Release.